Pharma Deals Review, Vol 2008, No 102 (2008)

Font Size:  Small  Medium  Large

Cephalon Signs Option Agreement for ImmuPharma’s First-in-class Lupus Drug

Helen Scrutton

Abstract


Cephalon has paid US$15 M upfront to obtain an option for an exclusive, worldwide licence to ImmuPharma’s Phase IIb lupus product, Lupuzor™. The deal provides ImmuPharma with some much-needed cash, while Cephalon gains low-risk access to a product which helps position its pipeline for longer-term growth.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.